Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award

Rhea-AI Summary

Phio Pharmaceuticals (NASDAQ: PHIO) has been nominated as a finalist for the Technology Disruptor of the Year award at Advanced Therapies Week 2025 in Dallas. The nomination highlights their patented INTASYL technology, a siRNA gene silencing platform designed to enhance immune cells' cancer-fighting capabilities.

Recent clinical data from their Phase 1b study of INTASYL compound PH-762 showed promising results, with one cutaneous squamous cell carcinoma patient achieving complete response (100% tumor clearance) and another achieving partial response (90% tumor clearance). The award ceremony will take place January 20-23, 2025, featuring judges from H.C. Wainwright & Co., Gama Biosciences, and Propel Biosciences.

Positive

• Phase 1b clinical trial of PH-762 showed significant efficacy with 100% tumor clearance in one patient and 90% in another
• Recognition as Technology Disruptor of the Year finalist validates INTASYL technology platform

Negative

• None.

Insights

Medical Research Analyst

This news about being a Technology Disruptor of the Year Award finalist, while acknowledging the company's innovative INTASYL technology, is not materially significant for investors. The article mentions clinical data showing positive responses in their Phase 1b study, but this information appears to be a recap of previously disclosed results rather than new data. While awards and recognition can enhance company credibility, they typically don't have direct impact on stock performance or company financials. The event is also scheduled for next year, making this a forward-looking announcement without immediate material impact.

Award is being presented during Advanced Therapies Week 2025 in Dallas

Marlborough, Massachusetts--(Newsfile Corp. - December 10, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO),) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL^® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio today announced the company is a finalist for the Technology Disruptor of the Year. The awards are part of Advanced Therapies Week 2025, a cell and gene conference that's taking place January 20-23, 2025 in Dallas, Texas.

According to the conference organizers, the award "celebrates exceptional contributions to the field of cell and gene therapy through technological innovation. It is awarded to organizations and individuals who have significantly advanced their industry by effectively successfully implementing and utilizing new technologies."

Phio's nomination focuses on its patented INTASYL technology, a unique siRNA technology that is able to silence any gene in the human genome. INTASYL compound PH-762 is currently completing a Phase 1b clinical study. Phio recently presented data from its second cohort showing one patient with cutaneous squamous cell carcinoma in the 2nd cohort achieved a complete response (100% tumor clearance) while a second patient with squamous cell carcinoma achieved a partial response (90% tumor clearance).

This is the first year the Award is being presented and this year's judges include: Michael Meyers, Vice Chairman and Head of M&A and Strategic Advisory Services at H.C. Wainwright & Co.; Phil Vanek, Chief Technology Officer at Gama Biosciences; and Susan Nichols, CEO of Propel Biosciences.

"We are pleased to see the mounting recognition for siRNA therapy and our INTASYL technology in particular, as revolutionary treatment in oncological disease," said Robert Bitterman, CEO, Phio Pharmaceuticals Corporation.

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company advancing its proprietary INTASYL siRNA gene silencing technology to eliminate cancer.  INTASYL can target and silence virtually any gene with high degree of specificity across a wide range of cell types and tissues. INTASYL is designed to enhance the ability of immune cells to more effectively kill tumor cells.  INTASYL has also demonstrated enhancement adoptive cell therapy. Notably, INTASYL is a self-delivering RNAi technology focused on immuno-oncology therapeutics without the need for formulation enhancements or manipulations to reach its target.

Phio's lead clinical program, PH-762, is an INTASYL compound that silences PD-1. PH-762 is a potential non-surgical treatment for skin cancers. The on-going Phase 1b trial (NCT# 06014086) received FDA clearance for an Investigational New Drug Application to evaluate PH-762 in the treatment of cutaneous SCC, melanoma and Merkel cell carcinoma in second quarter of 2023.

For additional information, visit the Company's website, www.phiopharma.com.  

Forward Looking Statements 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. Examples of forward-looking statements contained in this press release include, among others, the possibility that our INTASYL^® siRNA gene silencing technology will make the body's immune cells more effective in killing cancer cells and statements regarding our commercial and clinical strategy, development plans and timelines and other future events. 

These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control.  Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law. 

Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/233105

FAQ

What are the recent clinical results for Phio Pharmaceuticals' (PHIO) PH-762 trial?

In the Phase 1b trial's second cohort, one patient with cutaneous squamous cell carcinoma achieved complete response (100% tumor clearance), while another patient achieved partial response (90% tumor clearance).

When and where will Phio Pharmaceuticals (PHIO) receive the Technology Disruptor award nomination?

The award ceremony will take place during Advanced Therapies Week 2025, scheduled for January 20-23, 2025, in Dallas, Texas.

What is Phio Pharmaceuticals' (PHIO) INTASYL technology?

INTASYL is a patented siRNA technology capable of silencing any gene in the human genome, designed to make immune cells more effective in killing cancer cells.